PE20090996A1 - Derivados de pirrolopirimidina como inhibidores de cinasa jak3 - Google Patents

Derivados de pirrolopirimidina como inhibidores de cinasa jak3

Info

Publication number
PE20090996A1
PE20090996A1 PE2008000586A PE2008000586A PE20090996A1 PE 20090996 A1 PE20090996 A1 PE 20090996A1 PE 2008000586 A PE2008000586 A PE 2008000586A PE 2008000586 A PE2008000586 A PE 2008000586A PE 20090996 A1 PE20090996 A1 PE 20090996A1
Authority
PE
Peru
Prior art keywords
pyrimidine
amino
members
pirrolo
phenyl
Prior art date
Application number
PE2008000586A
Other languages
English (en)
Inventor
Solana Jorge Salas
Rosales Carmen Almansa
Soliva Robert Soliva
Ustrell Montserrat Fontes
Escobar Marc Vendrell
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of PE20090996A1 publication Critical patent/PE20090996A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRROLOPIRIMIDINA DE FORMULA (I), DONDE Cy1 ES FENILO O HETEROCICLO AROMATICO DE 5 O 6 MIEMBROS UNIDO AL GRUPO NH A TRAVES DE UN ATOMO DE CARBONO Y QUE PUEDE CONTENER DE 1 A 4 HETEROATOMOS SELECCIONADOS DE ENTRE N, O Y S; Cy2 ES UN HETEROCICLO MONOCICLICO DE 3 A 7 MIEMBROS O BICICLICO DE 6 A 11 MIEMBROS QUE CONTIENE DE 1 A 4 HETEROATOMOS SELECCIONADOS DE N, O Y S. SON COMPUESTOS PREFERIDOS: 2-[4-(4-MORFOLINO)FENIL]AMINO-4-(PIPERIDIN-1-IL)-7H-PIRROLO[2,3-d]PIRIMIDINA, 4-(2-AZABICICLO[2.2.1]HEPTAN-2-IL)-2-(3-FLUORO-4-METOXIFENIL)AMINO-7H-PIRROLO[2,3-d]PIRIMIDINA, (R)-2-(3-AMINOSULFONILFENIL)AMINO-4-(3-(N-METILAMINO)PIRROLIDIN-1-IL)-7H-PIRROLO[2,3-d]PIRIMIDINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA JAK, PARTICULARMENTE JAK3, Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES E INFLAMATORIAS, NEURODEGENERATIVAS, PROLIFERATIVAS, ENTRE OTRAS
PE2008000586A 2007-04-02 2008-03-31 Derivados de pirrolopirimidina como inhibidores de cinasa jak3 PE20090996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07380088 2007-04-02

Publications (1)

Publication Number Publication Date
PE20090996A1 true PE20090996A1 (es) 2009-07-15

Family

ID=38475914

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000586A PE20090996A1 (es) 2007-04-02 2008-03-31 Derivados de pirrolopirimidina como inhibidores de cinasa jak3

Country Status (16)

Country Link
US (1) US20110160185A9 (es)
EP (1) EP2142550A1 (es)
JP (1) JP2010523522A (es)
KR (1) KR20100015353A (es)
CN (1) CN101679440A (es)
AR (1) AR065901A1 (es)
AU (1) AU2008234822A1 (es)
BR (1) BRPI0809992A2 (es)
CA (1) CA2682646A1 (es)
CL (1) CL2008000946A1 (es)
IL (1) IL201073A0 (es)
MX (1) MX2009010595A (es)
PE (1) PE20090996A1 (es)
RU (1) RU2009140319A (es)
TW (1) TW200904442A (es)
WO (1) WO2008119792A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2723185A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010034740A1 (en) * 2008-09-23 2010-04-01 Palau Pharma, S.A. (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
WO2010063634A1 (en) 2008-12-05 2010-06-10 F. Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
JP5719840B2 (ja) * 2009-06-08 2015-05-20 武田薬品工業株式会社 Ｊａｋの阻害剤としてのジヒドロピロロナフチリジノン化合物
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CA2778680C (en) * 2009-10-29 2016-12-13 Carmen Almansa Rosales N-containing heteroaryl derivatives as jak3 kinase inhibitors
WO2012003829A1 (en) * 2010-07-09 2012-01-12 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
KR101541086B1 (ko) * 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
US20130225578A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030924A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
EP2782579B1 (en) 2011-11-23 2019-01-02 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
ES2827233T3 (es) * 2013-01-18 2021-05-20 Guangzhou Maxinovel Pharmaceuticals Co Ltd Compuesto heterocíclico de cinco y seis miembros, y método de preparación, composición farmacéutica y uso del mismo
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CN106458914B (zh) * 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物
CN105315285B (zh) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
NO2721710T3 (es) * 2014-08-21 2018-03-31
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3778604A1 (en) 2015-02-13 2021-02-17 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN104876934B (zh) * 2015-05-12 2017-08-11 山东大学 一种含氮杂环苯基哌啶类化合物及其制备方法与应用
ES2753159T3 (es) * 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN110526915B (zh) * 2018-05-25 2022-02-01 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂的制备方法
CA3118488A1 (en) 2018-11-05 2020-05-14 Avista Pharma Solutions, Inc. Chemical compounds
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20220242870A1 (en) * 2019-05-17 2022-08-04 Voronoi Inc. Heterocycle-fused pyrimidine derivative and use thereof
CN110183471B (zh) * 2019-05-21 2022-02-15 江苏大学 一种哌嗪类衍生物及制备方法及应用
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
WO2022216097A1 (ko) * 2021-04-08 2022-10-13 주식회사 스탠다임 신규한 lrrk2 억제제
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
WO2024006916A1 (en) * 2022-06-29 2024-01-04 Aerie Pharmaceuticals, Inc. Azetidinyl pyrimidines and uses thereof as jak inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR100415791B1 (ko) * 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
MX2007009429A (es) * 2005-02-03 2008-03-18 Vertex Pharma Pirrolopirimidinas utiles como inhibidores de proteinas cinasas.
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR065901A1 (es) 2009-07-08
AU2008234822A1 (en) 2008-10-09
BRPI0809992A2 (pt) 2014-10-14
EP2142550A1 (en) 2010-01-13
JP2010523522A (ja) 2010-07-15
US20100113420A1 (en) 2010-05-06
US20110160185A9 (en) 2011-06-30
RU2009140319A (ru) 2011-05-10
CN101679440A (zh) 2010-03-24
TW200904442A (en) 2009-02-01
CL2008000946A1 (es) 2008-10-10
CA2682646A1 (en) 2008-10-09
WO2008119792A1 (en) 2008-10-09
KR20100015353A (ko) 2010-02-12
MX2009010595A (es) 2009-10-22
IL201073A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
PE20090996A1 (es) Derivados de pirrolopirimidina como inhibidores de cinasa jak3
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
NZ588830A (en) Inhibitors of protein kinases
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
CL2009001152A1 (es) Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
MX2012006994A (es) Agente antiplaquetas novedoso.
UA116768C2 (uk) Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф
TW200612936A (en) Indole derivatives
NO20082496L (no) Pyrazinderivater
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
DE602008003404D1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物

Legal Events

Date Code Title Description
FC Refusal